 |
Hugel |
[Alpha Biz= Kim Jisun] Hugel announced on the 20th (local time) that it has received product approval from the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) for its botulinum toxin, 'Botulax.'
Botulax has been approved for use in five indications: eyelid spasm, crow's feet, frown lines, upper limb spasticity after a stroke, and clubfoot in children with cerebral palsy. Hugel plans to officially launch Botulax in the UAE by the end of April.
Hugel aims to maximize synergy with its HA filler 'Revolax,' which received approval and is already being sold in the UAE in 2023, to build an integrated aesthetic portfolio.
The Middle East and North Africa (MENA) region is one of the fastest-growing markets in the global medical aesthetics industry, driven by high economic growth and population increase, leading to a surge in demand for beauty treatments and medical services. Hugel is also in the process of obtaining botulinum toxin approval in Saudi Arabia and Qatar.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
